Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction: Glycomics, known as the study of the structure and function of glycans, is a rapidly growing field. Glycosaminoglycan (GAG) chains are made of repeating disaccharide units that are attached to proteoglycan core proteins on adherent animal cell surfaces and in extracellular matrices. Chondroitin sulfate (CS) is a glycosaminoglycan that consists of repeating disaccharide units of [(GlcA?(1-3)GalNAc?(1-4)]. Three types of CS exist, CS-A, CS-B, and CS-C. Presently, the field of glycomics lacks an effective analytical method for the isomeric differentiation and relative quantification of GAGs in small (1-10 microgram) biological samples. This work describes the development of a method for quantification of glycoforms using a stable isotopic labeling technique, and its application to the sulfated GAGs. Methods: CS samples, both standard and unknown, were partially depolymerized by chondroitin lyase ABC. The standard CS was then derivatized via a reductive amination reaction with 2-anthranilic acid, while the unknown CS was derivatized with 2-anthranilic-3,4,5,6-d4 acid. The derivatized CS samples were cleaned and the excess reagent removed via a cellulose microspin column. Equimolar mixtures of the standard and unknown CS samples were made. The isotopically labeled CS mixture was subjected to size exclusion liquid chromatography in a 10% acetonitrile, 50 mM ammonium formate buffer with on-line electrospray ionization mass spectrometrometric detection in the negative mode. Automated tandem mass spectrometry was acquired and quantification of unknown samples was found using relative ion abundances of the diagnostic ions. Abstract: A sample of lyase digested CSA was used as a reference against which all unknown CS samples were compared. The reference sample was reductively aminated with d0-anthranilic acid and the unknown CS samples with d4-anthranilic acid. The samples were mixed and separated using SEC with on-line negative ESI MS/MS detection. The HPLC flow was split prior to the sample inlet, allowing 10 microliters/minute of flow into the mass spectrometer. Tandem MS was performed using the automated MSn feature of the ion trap. The isolation and fragmentation windows were set to 12.0 u so that CID spectra of both heavy and light forms were acquired simultaneously. Tandem MS resulted in Y ions and [M-H-SO3] ions containing the reducing end and differing by four mass units, and B ions that are isobaric for both heavy and light forms of AA-labeled CS oligosaccharides. The abundances of Y and [M-H-SO3] heavy and light ions were used for glycoform distribution predictors for unknown CS samples. The method is validated by acquiring automated tandem mass spectra on several isotopically labeled CS mixtures in triplicate. The mixtures were analyzed and the percent total ion abundances of light and heavy predictive ions containing the reducing end were calculated. Light and heavy predictive ion contributions from the unknown were then put into a set of three equations. The three equations were solved for three unknowns that represent the percentage of CSA, CSB, and CSC in a mixture. The results demonstrate that tandem mass spectrometry can be used for the isotopic quantification of glycoforms of chondroitin sulfate.
No Sub Projects information available for 5P41RR010888-10 7175
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P41RR010888-10 7175
Patents
No Patents information available for 5P41RR010888-10 7175
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P41RR010888-10 7175
Clinical Studies
No Clinical Studies information available for 5P41RR010888-10 7175
News and More
Related News Releases
No news release information available for 5P41RR010888-10 7175
History
No Historical information available for 5P41RR010888-10 7175
Similar Projects
No Similar Projects information available for 5P41RR010888-10 7175